BAD BUGS, WHICH DRUGS

A Review of Drug-Resistant Pathogens and Pharmacotherapy

Kaitlyn DeWeerdt, PharmD, BCPS
Disclosures

• This program may contain the mention of drugs or brands presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand or drug.

• The presenter has no personal conflicts of interest to disclose.
Overview

• Epidemiology
• Microbiology background
• Methicillin Resistant Staphylococcus aureus
• Extended Spectrum Beta-Lactamases
• Carbapenem Resistant Enterobacteriaceae
• Pharmacokinetics
Definitions

- MRSA  methicillin resistant *Staphylococcus aureus*
- VRE   vancomycin resistant *Enterococcus*
- CRE   carbapenem resistant Enterobacteriaceae
- KPC   *Klebsiella pneumoniae* carbapenemase
- ESBL  extended spectrum beta-lactamase
EPIDEMIOLOGY
Epidemiology

• International problem
  • 2004: IDSA made statement to FDA → “Bad Bugs, No Drugs” born
  • Outlines the crisis of growing antibiotic resistance

Sources: IDSA. Bad Bugs No Drugs. 2004.
Image from:
http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10x20
Figure 1. Hospital stays with methicillin–resistant Staphylococcus aureus (MRSA) infections, 1993–2005

Source: AHRQ, Center for Delivery, Organization, and Markets, Healthcare Cost and Utilization Project, Nationwide Inpatient Sample, 1993-2005

Source: Image from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb35.jsp
Antibiotic Prescriptions per 1000 Persons of All Ages According to State, 2010

The frequency with which doctors prescribe antibiotics varies greatly from state to state. The reasons for this variation are being studied and might suggest areas where improvements in antibiotic prescribing (fewer unnecessary prescriptions) would be most helpful.

Source: CDC. 2013.
ANTIMICROBIAL DRUGS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS
ACTIVELY MARKETED IN 2015
SALES AND DISTRIBUTION DATA
REPORTED BY DRUG CLASS

Source: FDA. Dec 2016.
Brief History of Resistance

- **Penicillin**
  - P: 1943
  - R: 1940

- **Erythromycin**
  - P: 1953
  - R: 1968

- **Methicillin**
  - P: 1960
  - R: 1962

- **Linezolid**
  - P: 2000
  - R: 2001
Background

• Bacteria classifications
  • Gram positive vs. gram negative
  • Aerobe vs. anaerobe
  • Typical vs. atypical
Background

• Gram positives (focus on these today)
  • *Staphylococcus*
  • *Streptococcus*
  • *Enterococcus*

Source: Image from: https://www.atsu.edu/faculty/chamberlain/mosdoh/gramstainingrules.htm
Background

• Gram negatives (focus on these today)
  • *E. coli*
  • *Klebsiella*
  • *Pseudomonas*

Source: Image from: https://www.atsu.edu/faculty/chamberlain/mosdoh/gramstainingrules.htm
Mechanisms of Resistance

• Efflux pumps
• Competitive inhibition
• Change in binding site
• Drug inactivation
Mechanisms of Resistance

Background

- Concept: selective pressure

Source: CDC 2013.
Background

- Genetic mutation
- Bacterial genetic transfer
  - Plasmid mediated
  - Transposon mediated

Image from: https://www.twenty20.com/photos/2436b635-9ee9-448b-9ad4-e47d824a07fa
How antibiotic resistance spreads

1. Chromosomal DNA
   - Resistant bacteria
   - Pilius
   - Non-Resistant bacteria

2. 
   - Resistant DNA copied to receiving cell

3. 
   - Resistant DNA

4. 
   - Resistant DNA
   - Resistant

SPECIFIC PATHOGENS
MRSA

• Well-studied pathogen
• Encoded by the *mecA* gene
  • *mecA* is encoded on a mobile genetic element
  • *mecA* encodes for a protein that is not bound by antibiotics well so cell wall remains intact
• Confers resistance to:
  • Nafcillin, oxacillin, dicloxacillin
MRSA

• Optimal treatment choices:
  • Vancomycin
  • TMP/SMX
  • Doxycycline
  • Linezolid
  • Daptomycin

• Future directions
Dalbavancin

- DISCOVER-1 and DISCOVER-2 trials
  - Compared dalbavancin vs. vancomycin transition to linezolid
  - Dosing strategy: 1000mg IV on day 1, 500mg IV on day 8
  - Found to be noninferior for skin/soft tissue infections

- Offers unique dosing strategy

Oritavancin

• SOLO-1
  • Compared oritavancin to vancomycin
  • Dosing strategy: 1200mg IV x 1
  • Found to be noninferior for skin/soft tissue infections

• SOLO-2
  • Same trial design as SOLO-1
  • Again noninferior

Corey GR. Clin Infect Dis. 2015.
Patient Case—Poll Question

• JK is a 48-year-old female presenting to the emergency department with cellulitis. She has failed outpatient oral antibiotic therapy, but does not appear clinically unstable. If available at your institution, which of the following could be appropriate?
  • A) Dalbavancin 1000 mg IV x 1 today, then 500 mg on day 8
  • B) Oritavancin 2000 mg IV x 1 today
  • C) Daptomycin 500 mg IV every 12 hours
  • D) Linezolid 600 mg PO every 24 hours
Patient Case—Poll Response

- JK is a 48-year-old female presenting to the emergency department with cellulitis. She has failed outpatient oral antibiotic therapy, but does not appear clinically unstable. If available at your institution, which of the following could be appropriate?
  - A) Dalbavancin 1000 mg IV x 1 today, then 500 mg on day 8
  - B) Oritavancin 2000 mg IV x 1 today
  - C) Daptomycin 500 mg IV every 12 hours
  - D) Linezolid 600 mg PO every 24 hours
ESBL

- Encoded by variety of genes:
  - TEM
  - SHV
  - CTX-M
  - AMP-C

- Confers resistance to:
  - Cephalosporins
  - Aztreonam
  - Piperacillin/tazobactam (?)

ESBL

• Ambler classification
  • Based on structure
• Other classifications
  • Based on function
• Plasmid or chromosome mediated

ESBL

• Optimal treatments
  • Carbapenems
• Future directions
  • Ceftazidime/avibactam
  • Ceftolozane/tazobactam
RECLAIM

• Compared ceftazidime/avibactam to meropenem for complicated intraabdominal infections
  • Found to be noninferior with combination
  • Used 5-14 days of therapy
  • Allowed for addition of gram positive coverage as needed
• Completed microbiological comparison

RECAPTURE

- Comparison of ceftazidime/avibactam to doripenem for complicated urinary tract infections
  - Found to be at least noninferior, and superior in some subsets of patients
  - 10-14 days total therapy
- Completed microbiological comparison
  - Similar pathogens and cure rates

REPRISE

• Comparison of ceftazidime/avibactam with best available therapy for complicated intra-abdominal infections or urinary tract infections
  • Pathogens were required to be resistant to ceftazidime alone
  • 5 to 14 days of therapy
    • Included: meropenem, imipenem, doripenem, colistin
    • Intra-abdominal infections only: tigecycline
    • Combination therapy permitted
• Found to be noninferior to best available therapy for both indications

ASPECT-cIAI

- Compared ceftolozane/tazobactam + metronidazole to meropenem for complicated IAI
  - Found to be noninferior
  - Allowed for 5-10 days of IV therapy, extension if criteria met
- Microbiological evaluation done, noninferior

ASPECT-cUTI

• Compared ceftolozane/tazobactam to levofloxacin for complicated UTI
  • 7 days of therapy used
  • No other therapy permitted
• Results: ceftolozane/tazobactam was superior per the combined primary endpoint
  • Microbiological cure was superior, but clinical cure rates were not different

CRE

- Encoded by a few genes:
  - KPC
  - NDM
- Confers resistance to:
  - Carbapenems
• Optimal treatments:
  • Typically combination therapy
  • Colistin/polymyxin
  • Tigecycline
  • Aminoglycosides
  • Fosfomycin
    • Urinary tract infections only, specific pathogens
  • Carbapenems
    • Potentially as extended infusions

Colistin Resistance

- Found in case reports
- *mcr*-1 gene
- Usually changes lipopolysaccharide
- Ideal treatment unclear

PHARMACOKINETICS
PKPD

• High dose extended interval aminoglycosides
  • Concentration dependent antibiotic
  • Typical dosing 7mg/kg every 24 hours
  • Achieves post-antibiotic effect

PKPD

• Extended infusion beta lactams
  • Piperacillin/tazobactam
  • Meropenem
  • Cephalosporins?

PKPD Patient Case–Poll Question

• Patient DY is growing *Pseudomonas aeruginosa* from a blood culture. It is found to be resistant to fluoroquinolones. Which antibiotic option could be appropriate for this patient?
  • A) Ceftriaxone 2g IV Q 12 hours
  • B) Piperacillin/tazobactam 3.375g IV Q 8 hours over 4 hours each
  • C) Cefepime 2g IV Q 12 hours over 15 minutes each
  • D) Levofloxacin 750mg IV Q 24 hours
Patient DY is growing *Pseudomonas aeruginosa* from a blood culture. It is found to be resistant to fluoroquinolones. Which antibiotic option could be appropriate for this patient?

- A) Ceftriaxone 2g IV Q 12 hours
- B) Piperacillin/tazobactam 3.375g IV Q 8 hours over 4 hours each
- C) Cefepime 2g IV Q 12 hours over 15 minutes each
- D) Levofloxacin 750mg IV Q 24 hours
PKPD

• Inhaled options for pneumonia/cystic fibrosis
  • Tobramycin
  • Colistin
  • Others

Where do we go from here?

• CDC’s Four Core Actions
  • Prevent the spread of infection
  • Track drug resistance
  • Improve antibiotic stewardship
  • Develop new drugs/diagnostic tests

Source: CDC. 2013.
Where do we go from here, continued

- Practice appropriate containment
  - Hand hygiene
  - Isolation appropriateness
- Antimicrobial stewardship
  - Less pressure on organisms will decrease resistance emergence
  - Right drug, right bug, right spectrum, right dose, right duration

Source: CDC. 2013.
Summary

• Antibiotic resistance is a growing problem
• Many pathogens exhibit resistance
• Optimal treatment may include new medications or alternate dosing strategies
• Pharmacists can be impactful in drug choice, dosing and monitoring
Resources

- CDC Antimicrobial Resistance Information: https://www.cdc.gov/drugresistance/index.html
- FDA NARMS: https://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/default.htm
QUESTIONS
References

References, continued


References, continued

References, continued


References, continued